ARCA BIOPHARMA, INC.

Profile

Company Names

ARCA BIOPHARMA, INC.

Addresses

11080 CIRCLEPOINT ROAD, SUITE 140, WESTMINSTER, CO 80020

8001 ARISTA PLACE, SUITE 430, BROOMFIELD, CO 80021

8001 ARISTA PLACE, SUITE 200, BROOMFIELD, CO 80021

Phone Numbers

720-940-2200

 

Entity Type:

CORPORATION

Industry:

PHARMACEUTICALS

Year Incorporated:

> 5 years ago

State Incorporated:

DELAWARE

Total Amount Raised:

$59,850,846.00

Number of Funding Rounds:

8
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
8
2015-06-16 
$51,650,404.00 
$51,650,404.00 
$0.00 
Equity 
7
2014-02-07 
$326,158.00 
$326,158.00 
$0.00 
 
6
2013-06-04 
$1,250,000.00 
$1,250,000.00 
$0.00 
 
5
2013-01-25 
$1,000,000.00 
$1,000,000.00 
$0.00 
Equity 
4
2012-12-18 
$250,000.00 
$250,000.00 
$0.00 
Equity 
3
2012-10-22 
$325,000.00 
$325,000.00 
$0.00 
Equity 
2
2011-12-22 
$4,549,285.00 
$4,549,285.00 
$0.00 
Equity 
1
2009-10-18 
$499,999.00 
$499,999.00 
$0.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
RICHARD 
B. 
BREWER 
DIRECTOR
ARCA BIOPHARMA, INC.   |  NILE THERAPEUTICS, INC.
MICHAEL 
R. 
BRISTOW 
EXECUTIVE OFFICER, DIRECTOR
ARCA BIOPHARMA, INC.
ROBERT 
E. 
CONWAY 
DIRECTOR
ARRAY BIOPHARMA INC   |  ARCA BIOPHARMA, INC.
KATHRYN 
E. 
FALBERG 
EXECUTIVE OFFICER
ARCA BIOPHARMA, INC.   |  AIMMUNE THERAPEUTICS, INC.   |  NUVATION BIO INC.
JEAN-FRANCOIS 
 
FORMELA 
DIRECTOR
ARCA BIOPHARMA, INC.   |  RESOLVYX PHARMACEUTICALS, INC.   |  HORIZON PHARMA, INC.   |  ANNOVATION BIOPHARMA, INC.   |  ARTEAUS THERAPEUTICS, LLC   |  COSTIM PHARMACEUTICALS INC.   |  CALORICS, INC.   |  NAVITOR PHARMACEUTICALS, INC.   |  INTELLIA THERAPEUTICS, INC.   |  IFM THERAPEUTICS, INC.   |  SPERO THERAPEUTICS, LLC   |  ATLAS VENTURE FUND XI, L.P.   |  IFM TRE, INC.   |  ATLAS VENTURE OPPORTUNITY FUND I, L.P.   |  TRANSLATE BIO, INC.   |  KORRO BIO, INC.   |  IFM QUATTRO, INC.   |  IFM CINQUE, INC.   |  IFM CONTINUA, INC.   |  ATLAS VENTURE FUND XII, L.P.   |  SCORPION THERAPEUTICS, INC.   |  SPERO THERAPEUTICS, INC.   |  ATLAS VENTURE OPPORTUNITY FUND II, L.P.   |  ATLAS VENTURE FUND XIII, L.P.   |  AMAGMA, INC.   |  IKENA ONCOLOGY, INC.   |  ANTARES THERAPEUTICS, INC.
J. 
WILLIAM 
FREYTAG 
DIRECTOR
GLOBEIMMUNE INC   |  ARCA BIOPHARMA, INC.   |  ARACELI BIOSCIENCES INC.
LINDA 
 
GRAIS 
DIRECTOR
GYNESONICS, INC   |  ARCA BIOPHARMA, INC.
LINDA 
S. 
GRAIS 
DIRECTOR
OCERA THERAPEUTICS, INC.   |  ARCA BIOPHARMA, INC.
THOMAS 
A. 
KEUER 
EXECUTIVE OFFICER
ARCA BIOPHARMA, INC.
TED 
W. 
LOVE 
DIRECTOR
AFFYMAX INC   |  ARCA BIOPHARMA, INC.   |  AMICUS THERAPEUTICS INC   |  ONCOTHYREON INC.   |  GLOBAL BLOOD THERAPEUTICS, INC.
DAN 
J. 
MITCHELL 
DIRECTOR
KALYPTO MEDICAL INC   |  ARCA BIOPHARMA, INC.
CHRISTOPHER 
D. 
OZEROFF 
EXECUTIVE OFFICER
ARCA BIOPHARMA, INC.
MARY 
K. 
PENDERGAST 
DIRECTOR
ARCA BIOPHARMA, INC.   |  AESRX, LLC
BRIAN 
L. 
SELBY 
EXECUTIVE OFFICER
ARCA BIOPHARMA, INC.
BURTON 
E. 
SOBEL 
DIRECTOR
ARCA BIOPHARMA, INC.
PATRICK 
M. 
WHEELER 
EXECUTIVE OFFICER
ARCA BIOPHARMA, INC.
RAYMOND 
L. 
WOOSLEY 
DIRECTOR
ARCA BIOPHARMA, INC.
JOHN 
L. 
ZABRISKIE 
DIRECTOR
ARRAY BIOPHARMA INC   |  ARCA BIOPHARMA, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2015-06-25
D
Link
PHARMACEUTICALS 
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835] 
DECLINE TO DISCLOSE 
Equity 
2015-06-16 
2014-02-20
D
Link
PHARMACEUTICALS 
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835] 
DECLINE TO DISCLOSE 
 
2014-02-07 
2013-06-17
D
Link
PHARMACEUTICALS 
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835] 
DECLINE TO DISCLOSE 
 
2013-06-04 
2013-02-01
D
Link
PHARMACEUTICALS 
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835] 
DECLINE TO DISCLOSE 
Equity 
2013-01-25 
2012-12-28
D
Link
PHARMACEUTICALS 
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835] 
DECLINE TO DISCLOSE 
Equity 
2012-12-18 
2012-10-31
D
Link
PHARMACEUTICALS 
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835] 
DECLINE TO DISCLOSE 
Equity 
2012-10-22 
2012-01-05
D
Link
PHARMACEUTICALS 
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835] 
DECLINE TO DISCLOSE 
Equity 
2011-12-22 
2009-10-26
D
Link
PHARMACEUTICALS 
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835] 
DECLINE TO DISCLOSE 
Equity 
2009-10-18 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
MTS SECURITIES, LLC
104059
JOSEPH E. BALAGOT
4007591
DAWSON JAMES SECURITIES, INC.
130645
MONIQUE MACLAREN
NONE
DAWSON JAMES SECURITIES, INC.
130645
ROTH CAPITAL PARTNERS LLC
15407
ROTH CAPITAL PARTNERS LLC
15407